IPR issues not a major impediment to India investment: Lilly R&D head
This article was originally published in Scrip
Executive Summary
India's intellectual property rights (IPR) regime, perceived by some multinational companies as inadequate, was not a major deterrent that led to Lilly zeroing in on China for its new research centre focused on diabetes.